XTL Biopharmaceuticals Ltd. (TLV:XTLB)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
2.000
0.00 (0.00%)
Aug 3, 2026, 5:13 PM IDT

XTL Biopharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-1.47-1.47-0.78-0.77-0.88-1.03
Net Income
-6.97-6.97-1.03-1.78-1.350.44
Earnings Per Share
-0.01-0.01-0.00-0.00-0.000.00
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.080.081.142.013.726.13
Total Debt
--0.14---
Net Cash (Debt)
0.080.081.012.013.726.13
Net Cash Growth
-95.58%-92.44%-49.90%-46.09%-39.27%1.41%
Net Cash Per Share
0.000.000.000.000.010.01

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1.03-1.03-1.62-0.71-0.9-1.05
Capital Expenditures
---0.05---
Free Cash Flow
-1.03-1.03-1.67-0.71-0.9-1.05
Free Cash Flow Growth
------

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----34.41